SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

Apimeds Pharmaceuticals US, Inc.
Date: May 5, 2025 · CIK: 0001894525 · Accession: 0001213900-25-039670

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-282324

Date
May 5, 2025
Author
D. Boral Capital LLC
Form
CORRESP
Company
Apimeds Pharmaceuticals US, Inc.

Letter

D. Boral Capital LLC

590 Madison Ave., 39th Floor

New York, NY 10022

May 5, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F St., NE

Washington, D.C. 20549

Re:

Apimeds Pharmaceuticals US, Inc. Registration Statement on Form S-1, as amended by that certain Post-Effective Amendment No. 3 (File No. 333-282324)

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, D. Boral Capital LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time on Monday, May 5, 2025, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Very truly yours,
D. Boral Capital LLC

Show Raw Text
CORRESP
 1
 filename1.htm

 D. Boral Capital LLC

 590 Madison Ave., 39th Floor

 New York, NY 10022

 May 5, 2025

 VIA EDGAR

 U.S. Securities and Exchange Commission

 Division of Corporate Finance

 100 F St., NE

 Washington, D.C. 20549

 Re:

 Apimeds Pharmaceuticals US, Inc.
 Registration Statement on Form S-1, as amended by that certain Post-Effective
 Amendment No. 3 (File No. 333-282324)

 Ladies and Gentlemen:

 Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933,
as amended, D. Boral Capital LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced
Registration Statement so that it will become effective at 5:00 p.m. Eastern Time on Monday, May 5, 2025, or as soon thereafter as practicable.

 Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably
anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus
as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating
dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended,
in connection with the above-referenced issue.

 Very truly yours,

 D. Boral Capital LLC

 By:
 /s/ Philip Wiederlight

 Name:
 Philip Wiederlight

 Title:
 COO and Supervisory Principal